Financials

  • Market Capitalization 24.51 M
  • Employee 14
  • Founded 2016
  • CEO N/A
  • Website www.barinthusbio.com
  • Headquarter United Kingdom
  • FIGI BBG00ZZPCP09
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-0.43
Preis-Umsatz-Verhältnis

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.

Nachrichten